STOCK TITAN

Aurinia Pharmaceuticals Inc. - AUPH STOCK NEWS

Welcome to our dedicated page for Aurinia Pharmaceuticals news (Ticker: AUPH), a resource for investors and traders seeking the latest updates and insights on Aurinia Pharmaceuticals stock.

Aurinia Pharmaceuticals Inc (symbol: AUPH) is a cutting-edge biopharmaceutical company headquartered at 5120-75 street, Edmonton, Canada. Specializing in the treatment of serious diseases with high unmet medical need, Aurinia is committed to providing innovative therapeutic solutions to patients worldwide. The company's flagship product, LUPKYNIS (voclosporin), is an investigational drug designed for the treatment of lupus nephritis (LN), a severe renal complication of lupus. This groundbreaking treatment underscores Aurinia's focus on developing life-changing medications.

In recent years, Aurinia Pharmaceuticals has made significant strides in its research and development efforts, particularly in the United States, where it derives the majority of its revenue. The company has forged strategic partnerships with leading healthcare organizations and continues to explore new avenues for growth and innovation.

Financially, Aurinia has demonstrated strong performance, with consistent revenue growth driven by its robust pipeline of investigational drugs. The company's commitment to advancing its clinical programs and securing regulatory approvals positions it well for sustained success in the biopharmaceutical industry.

With a dedicated team of experts and a clear vision for the future, Aurinia Pharmaceuticals is poised to make a lasting impact on global healthcare. Investors and stakeholders can stay updated on the latest developments, financial results, and strategic initiatives through the company's regular news updates and investor relations communications.

Rhea-AI Summary

Aurinia Pharmaceuticals (NASDAQ: AUPH) has announced it will release its second quarter 2024 financial and operational results on Thursday, August 1, 2024, before markets open. The company's management team will host a conference call and webcast at 8:30 am ET on the same day to review the results and provide a general business update. Interested participants can join via phone or audio webcast, with a replay available on Aurinia's website afterwards.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.18%
Tags
-
Rhea-AI Summary

ILJIN SNT Co., , a major shareholder of Aurinia Pharmaceuticals (NASDAQ: AUPH), issued an open letter urging the company's board to respect the shareholder votes from the recent AGM. The 2024 AGM saw four directors, including CEO Peter Greenleaf, receiving less than majority support, triggering a call for their resignations as per the company's Majority Voting Policy. ILJIN emphasizes the importance of this change to enhance management performance and improve the company's stock performance. They plan to remain vigilant and advocate for new directors who can implement strategic changes to restore shareholder value.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.55%
Tags
none
-
Rhea-AI Summary

Aurinia Pharmaceuticals (NASDAQ: AUPH) announced participation in key investor healthcare conferences. The management team will engage in one-on-one meetings with investors at the Leerink Partners Therapeutics Forum in Boston on July 9-10, 2024. Additionally, they will attend the 3rd Annual H.C. Wainwright Virtual Kidney Conference on July 15, 2024. These events aim to foster investor relations and provide updates on Aurinia's therapeutic advancements.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.09%
Tags
conferences
Rhea-AI Summary

Aurinia Pharmaceuticals announced the results of its 2024 annual general meeting held on June 14, 2024. Shareholders re-elected five of nine incumbent directors. Four directors, including CEO Peter Greenleaf, received less than majority support and have submitted conditional resignations. The Board will decide on these resignations within 90 days. The re-appointment of PricewaterhouseCoopers as the independent auditor was approved. However, the advisory vote on executive compensation and the proposed amendment to the equity incentive plan did not receive majority support. The current equity incentive plan remains unchanged. Aurinia is committed to enhancing shareholder value and advancing its lupus nephritis treatment, LUPKYNIS.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.61%
Tags
none
-
Rhea-AI Summary

Aurinia Pharmaceuticals presented data at the EULAR Congress 2024 showing the safety and efficacy of LUPKYNIS® (voclosporin) for treating lupus nephritis (LN). The data, from the AURORA Clinical Program, demonstrated that a triple immunosuppressive therapy using LUPKYNIS plus lower-dose MMF and low-dose steroids reduced proteinuria and steroid exposure more effectively than a dual therapy with high-dose glucocorticoids. Results indicated a >50% reduction in steroid exposure and faster achievement of urine protein creatinine ratio (UPCR) <0.5 mg/mg at six months. These findings support guidelines recommending LUPKYNIS as an initial therapy for active LN.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.61%
Tags
none
-
Rhea-AI Summary

Aurinia Pharmaceuticals (NASDAQ: AUPH) has issued a response to a letter from Lucien Selce, raising concerns about his proposals and credibility. The company highlights its strategic focus on commercial execution, maximizing free cash flow, and advancing its autoimmune pipeline. Aurinia reports having over $320M in cash and equivalents and being debt-free. The company criticized Selce's lack of transparency and specific strategy, noting his concerning background in illegal activities. Aurinia supports the re-election of its current board, as recommended by Glass Lewis. Recent positive business developments include a 46% increase in total net revenue and a 40% rise in net product revenue year-over-year.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.61%
Tags
none
Rhea-AI Summary

Aurinia Pharmaceuticals (NASDAQ: AUPH) has filed a supplement to its Proxy Statement dated June 3, 2024. The supplement aims to reduce the proposed increase in shares reserved under the Equity Incentive Plan from 11,375,000 to 8,500,000. The revised total increase of 8,500,000 Plan Shares now represents 22.7% of total shares outstanding as of April 30, 2024. The supplement amends the Proxy Statement to decrease the number of Plan Shares from 35,190,115 to 32,315,115. Shareholders are encouraged to read the supplement alongside the Proxy Statement. The document is available on Aurinia's website and on EDGAR and SEDAR+.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.68%
Tags
none
-
Rhea-AI Summary

Lucien Selce, who owns 2.2% of Aurinia Pharmaceuticals (NASDAQ: AUPH), has urged shareholders to withhold support for CEO Peter Greenleaf and the current Board of Directors in the upcoming AGM on June 14, 2024. Selce accuses the Board of manipulating AGM dates to benefit from stock-based compensation and depriving certain shareholders of their voting rights. A leading proxy advisory firm, ISS, has also recommended withholding support for three directors and voting against proposed executive compensation. Selce highlights the stock's decline from $10.71 to $5.42 and suggests a new Board and CEO to rejuvenate Aurinia's performance and governance.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.11%
Tags
none
-
Rhea-AI Summary

Aurinia Pharmaceuticals (NASDAQ: AUPH) announced its participation in the 2024 Jefferies Global Healthcare Conference in New York, scheduled from June 4-6, 2024.

The company's management will engage in one-on-one meetings with investors and deliver a presentation on June 5 from 8:00 to 8:25 AM Eastern Time.

A live webcast of the session will be accessible via the Investor section of Aurinia's website.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.26%
Tags
none
Rhea-AI Summary

Aurinia Pharmaceuticals (NASDAQ: AUPH) announced the cost-effectiveness of LUPKYNIS® (voclosporin) for treating lupus nephritis (LN) at the National Kidney Foundation Spring Clinical Meeting 2024. The updated analysis, consistent with a 2021 assessment, utilized the ICER AnalyticsTM LN model and found LUPKYNIS to be below the $150,000 willingness-to-pay threshold, costing $88,076 per QALY and $77,643 per evLYG for adults with active LN. For Black, Hispanic, and Latino patients, costs were $77,436 per QALY and $67,828 per evLYG. Additional data from the AURORA clinical program and the Enlight-LN registry highlighted the drug's sustained efficacy and reduced steroid use over three years. A propensity analysis indicated superior proteinuria reduction and decreased exposure to toxicities versus high-dose glucocorticoid regimens.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.59%
Tags
none

FAQ

What does Aurinia Pharmaceuticals Inc. specialize in?

Aurinia Pharmaceuticals specializes in developing treatments for serious diseases with high unmet medical need, including lupus nephritis.

Where is Aurinia Pharmaceuticals Inc. located?

Aurinia Pharmaceuticals Inc. is headquartered at 5120-75 street, Edmonton, Canada.

What is LUPKYNIS (voclosporin)?

LUPKYNIS (voclosporin) is an investigational drug developed by Aurinia for the treatment of lupus nephritis.

Where does Aurinia Pharmaceuticals derive most of its revenue?

Aurinia Pharmaceuticals derives the majority of its revenue from the United States.

What recent achievements has Aurinia Pharmaceuticals accomplished?

Aurinia has made significant progress in its R&D efforts, particularly with LUPKYNIS, and has formed strategic partnerships to advance its clinical programs.

How can investors stay updated on Aurinia Pharmaceuticals' latest news?

Investors can stay updated through the company's regular news updates and investor relations communications.

What is the significance of LUPKYNIS for Aurinia Pharmaceuticals?

LUPKYNIS is a key product in Aurinia's portfolio, targeting lupus nephritis and showcasing the company’s innovative capabilities.

What type of diseases does Aurinia Pharmaceuticals focus on?

Aurinia focuses on serious diseases with a high unmet medical need, such as lupus nephritis.

Has Aurinia Pharmaceuticals formed any partnerships?

Yes, Aurinia has formed strategic partnerships with leading healthcare organizations to advance its clinical programs.

What is the outlook for Aurinia Pharmaceuticals’ future?

With a robust pipeline and ongoing R&D efforts, Aurinia Pharmaceuticals is well-positioned for sustained success in the biopharmaceutical industry.

Aurinia Pharmaceuticals Inc.

Nasdaq:AUPH

AUPH Rankings

AUPH Stock Data

799.48M
143.02M
7.07%
40.35%
7.12%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
United States of America
EDMONTON